Tesamorelin
See our Evidence Standards for how we grade the research below.
What It Is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered for stability against enzymatic breakdown. Like sermorelin and CJC-1295, it binds the GHRH receptor on pituitary somatotrophs, stimulating a physiologic, pulsatile pattern of GH release that raises IGF-1. Tesamorelin holds a different status than almost everything else on this site: it's an FDA-approved medication, marketed as Egrifta (and reformulated as Egrifta SV in 2019), approved in 2010 specifically for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, a condition where antiretroviral therapy is associated with abnormal fat redistribution and increased cardiovascular risk.
The Evidence
Falutz J, Allas S, Blot K, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007 Dec 6;357(23):2359-2370. PMID: 18057338. Randomized, double-blind, placebo-controlled trial, the pivotal study behind FDA approval. 412 HIV-positive adults (86% men) with abdominal fat accumulation were randomized to daily subcutaneous tesamorelin 2 mg or placebo for 26 weeks. The primary endpoint, percent change in visceral adipose tissue by CT scan, showed a significant reduction with tesamorelin versus placebo. Secondary endpoints, triglycerides, the total-to-HDL cholesterol ratio, IGF-1, and self-assessed body image, also improved significantly.
Falutz J, Mamputu JC, Potvin D, et al. "Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data." Journal of Clinical Endocrinology & Metabolism. 2010 Sep;95(9):4291-4304. PMID: 20554713. Pooled analysis of two Phase 3 trials (including the one above), 806 participants total, each with a 26-week placebo-controlled phase followed by a 26-week safety extension. The pooled treatment effect on visceral adipose tissue was approximately 15.4% versus placebo, with liver fat and triglycerides also improving. This is the largest and most robust dataset supporting tesamorelin's approved indication.
Stanley TL, Feldpausch MN, Oh J, et al. "Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial." Lancet HIV. 2019 Oct 11. Randomized, double-blind, placebo-controlled trial, 61 HIV-positive adults with confirmed hepatic steatosis (liver fat content of 5% or more), given tesamorelin 2 mg daily or placebo for 12 months, followed by 6 months of open-label tesamorelin for all participants. Tesamorelin significantly reduced liver fat content and prevented progression of liver fibrosis compared with placebo, evaluated with paired liver biopsies, a more direct histological outcome than imaging alone. This trial extended tesamorelin's evidence base beyond its approved indication (visceral fat) into a related, genuinely severe complication (fatty liver disease and fibrosis) in the same HIV population.
What's Reported in Practice
Beyond its approved HIV-lipodystrophy indication, patients using tesamorelin off-label for general visceral-fat reduction and body composition commonly report similar benefits to what the trials found in the HIV population, along with improved sleep and cognitive clarity. The visceral-fat mechanism is the same regardless of population, so we think the core effect is plausible outside HIV lipodystrophy too, but the trials above were conducted specifically in people with HIV and antiretroviral-associated fat redistribution, a population with a particular metabolic profile. We haven't identified a trial of comparable size and rigor testing tesamorelin for visceral fat reduction in a general, non-HIV population.
What the Research Doesn't Yet Show
This is where we're most eager to see more research investment, not a mark against the compound; tesamorelin already has the strongest evidence base of any compound on this site. What it doesn't yet establish is how well the HIV-lipodystrophy findings generalize to people without HIV using it for general visceral-fat reduction or body composition, since that's a different population with different underlying metabolic drivers of visceral fat accumulation. The approved trials also didn't measure whether visceral-fat reduction translates into fewer actual cardiovascular events, only into risk markers and imaging; and studies confirm that visceral fat returns toward baseline once tesamorelin is stopped, so its benefit doesn't appear to be a lasting, one-time correction. A dedicated, similarly rigorous trial in a general (non-HIV) population using tesamorelin for visceral-fat reduction is exactly the study that would resolve the biggest remaining question about its off-label use.
FDA-approved (as Egrifta / Egrifta SV) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Used off-label, and via compounded formulations, for other indications. Sourcing and appropriateness are discussed at your visit.
Next Step
This page covers mechanism and evidence. Dosing and whether this is appropriate for you are individual clinical decisions made with your provider.
Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?